Result for
Tag: treatment
January 11, 2021
Continuation versus Discontinuation of Renin–Angiotensin System Inhibitors in Patients Admitted to Hospital with COVID-19: A Prospective, Randomised, Open-Label Trial
A prospective, randomized, open-label trial concluded that renin–angiotensin system inhibitors, which are commonly used to treat hypertension, could safely be continued in patients hospitalized with COVID-19. Between March 31 and August 20, 2020, 152 participants were randomly assigned to either continue or discontinue renin–angiotensin system inhibitor therapy. 16 (21%) participants in the continuation arm versus…
January 8, 2021
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
[pre-print; not peer-reviewed] A randomized trial of the IL-6 receptor antagonists tocilizumab and sarilumab showed better patient outcomes, including 90-day survival and time to discharge, in critically ill adult COVID-19 patients who were receiving respiratory or cardiovascular organ support in intensive care units. According to this preliminary report from the randomized trial, in-hospital mortality was…
January 7, 2021
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
In a randomized, double-blind, placebo-controlled trial of non-hospitalized adults aged ≥75 years (n=160) with mild COVID-19, patients who received convalescent plasma within 72 hours after onset of symptoms were 48% less likely to develop severe respiratory disease than patients receiving placebo (RR = 0.52, 95% CI: 0.29-0.94). Risk of severe disease was 60% lower (RR…
December 23, 2020
ACTIV-3/TICO LY-CoV555 Study Group. (Dec 22, 2020). A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
A randomized clinical trial among patients hospitalized with COVID-19 that aimed to assess the effect of LY-CoV555, a neutralizing monoclonal antibody, was halted due to futility after 314 patients had undergone infusion with either the antibody or a placebo. Patients who received the antibody infusion did not have better clinical outcomes at day five than…
December 18, 2020
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Tocilizumab reduced the rate of mechanical ventilation, but did not prevent deaths among hospitalized COVID-19 patients. In a randomized trial of patients hospitalized with COVID-19 pneumonia who were not receiving mechanical ventilation, tocilizumab reduced the likelihood of progression to the composite outcome of mechanical ventilation or death, but did not improve survival. The cumulative percentage…
December 17, 2020
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
An interim analysis of the ongoing randomized placebo-controlled phase 1-3 trial of the antibody cocktail REGN-COV2 among non-hospitalized patients with COVID-19 (n=228) found a larger reduction in SARS-CoV-2 viral load among patients in the treatment group vs. the placebo group, with a mean difference of -0.41 log10 copies per milliliter (95% CI, −0.71 to −0.10)….
Inclusion of Pregnant Women in COVID-19 Treatment Trials: A Review and Global Call to Action
A review of COVID-19 treatment trials throughout different timepoints in the pandemic found that a substantial portion of trials listed pregnancy as an exclusion criterion. A review in April found that 80% (124/155) of trials excluded pregnant persons, with a similar finding of 75% (538/722) in July. Among studies focusing on therapeutic drugs (including remdesivir),…
December 14, 2020
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
Receiving baricitinib, a kinase inhibitor that blocks a cytokine signaling pathway, in addition to remdesivir, was associated with shorter recovery time (median 7 vs. 8 days, RR=1.2) and higher odds of improvement at day 15 (OR=1.3) in a double-blind, randomized, placebo-controlled trial involving 1,033 patients hospitalized with COVID-19. The estimate for the risk of death through…
Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY) a Randomised Controlled Open-Label Platform Trial
[Preprint, not peer-reviewed] Receiving azithromycin in addition to usual care was not associated with 28-day mortality (19% vs. 19%) or the duration of hospitalization (12 days vs. 13 days) in a randomized, controlled trial among 7,764 patients hospitalized with COVID-19 in the UK. Results were consistent across subgroups of age, sex, ethnicity, level of respiratory…
December 11, 2020
Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis
A systematic review and meta-analysis found inconclusive results on the efficacy of remdesivir for treating patients with COVID-19 due to the lack of adequately powered and fully reported randomized trials evaluating efficacy and harms of its use in adult hospitalized COVID-19 patients. Piscoya et al. (Dec 10, 2020). Efficacy and harms of remdesivir for the…
Previous page Next page